Novo Nordisk A/S Common Stock (NVO)
R&D Expense Growth
72.96%
Quarterly · Period ending:
NVO R&D Expense Growth
Latest reported72.96%period ending
Latest reported72.96%period ending
NVO Quarterly R&D Growth (QoQ) (0.00% → 72.96%)
Latest values, visible window
High-resolution chart · PNG
NVO r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 72.958% | |
| -29.7925% | |
| -4.8399% | |
| 31.6766% | |
| 13.4071% | |
| -25.3152% | |
| 45.468% | |
| -41.3089% | |
| 87.8457% | |
| -17.7247% | |
| 28.6909% | |
| 14.0452% | |
| 5.9304% | |
| -16.7842% | |
| 43.5292% | |
| 9.9551% | |
| -1.5943% | |
| -7.5639% | |
| 32.4553% | |
| 7.8093% | |
| 0% | |
| -12.0232% | |
| 14.6254% | |
| 18.8393% | |
| -12.8674% | |
| -13.8458% | |
| 21.744% | |
| 1.237% | |
| 32.823% | |
| -41.0651% | |
| 24.6981% | |
| 10.5583% | |
| -0.7528% | |
| -16.6206% | |
| 19.6815% | |
| -2.519% | |
| 3.8005% | |
| -26.4206% | |
| 29.2655% | |
| 3.8127% | |
| 0.8172% | |
| -18.0962% | |
| 22.6513% | |
| 8.369% | |
| -6.6154% | |
| -15.912% | |
| 5.7745% | |
| 18.8293% | |
| -2.9356% | |
| -11.161% | |
| 27.585% | |
| 2.9466% | |
| 2.1829% | |
| -17.2274% | |
| 22.6595% | |
| 2.1069% | |
| 2.2337% | |
| -8.9026% | |
| 21.6085% | |
| -2.5829% | |
| 1.441% | |
| -16.2706% | |
| 18.8097% | |
| -5.4232% | |
| 14.2187% | |
| -10.7248% | |
| 26.6985% | |
| 1.8929% | |
| 6.0206% | |
| -29.1683% | |
| 55.9326% | |
| -20.2939% | |
| 6.6215% | |
| -45.7795% | |
| 98.8107% | |
| -1.775% | |
| 6.583% | |
| -13.8803% | |
| 28.4646% | |
| -0.8075% | |
| 5.4985% | |
| -7.9649% | |
| 25.8038% | |
| 2.8687% | |
| 7.6388% | |
| -14.465% | |
| 19.7235% | |
| 10.4095% | |
| -4.4868% | |
| -11.8759% | |
| 10.8991% | |
| 5.0077% | |
| 2.9715% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |